Chemical Property of (1S,3S,5S)-2-[(2S)-2-amino-2-[(1r,3R,5R,7S)-3-hydroxyadamantan-1-yl]acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile
Chemical Property:
- Appearance/Colour:White powder
- Vapor Pressure:2.51E-14mmHg at 25°C
- Refractive Index:1.64
- Boiling Point:548.7 °C at 760 mmHg
- PKA:15.12±0.40(Predicted)
- Flash Point:285.6 °C
- PSA:90.35000
- Density:1.35 g/cm3
- LogP:1.79618
- Storage Temp.:2-8°C
- Solubility.:DMSO (Slightly), Methanol (Sparingly)
- XLogP3:0.7
- Hydrogen Bond Donor Count:2
- Hydrogen Bond Acceptor Count:4
- Rotatable Bond Count:2
- Exact Mass:315.19467705
- Heavy Atom Count:23
- Complexity:609
- Purity/Quality:
-
99.0%min *data from raw suppliers
Saxagliptin *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- Statements:
28-38-41-48
- Safety Statements:
24/25-26-28-36/37/39
- MSDS Files:
-
SDS file from LookChem
Useful:
- Drug Classes:Antidiabetic Agents
- Canonical SMILES:C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N
- Isomeric SMILES:C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34C[C@H]5C[C@@H](C3)CC(C5)(C4)O)N
- Recent ClinicalTrials:Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus Aged 10 to Below 18 Years Old
- Recent EU Clinical Trials:A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase
- Recent NIPH Clinical Trials:Effect of omarigliptin on glucose variability and oxidative stress in type 2 diabetes patients
-
Uses
Saxagliptin is a potent and selective reversible inhibitor of dipeptidyl peptidase-4, which is being developed for the treatment of type 2 diabetes. It is absorbed rapidly after oral administration an
d has a pharmacokinetic profile compatible with once daily dosing. Saxagliptin is a potent and selective reversible inhibitor of dipeptidyl peptidase-4, which is being developed for the treatment of type 2 diabetes. It is absorbed rapidly after oral administration and has a pharmacokinetic profile compatible with once daily dosing.
-
Clinical Use
Saxagliptin, previously identified as BMS-477118, is an oral
hypoglycemic of the dipeptidyl peptidase-4 (DPP-4) inhibitor class
developed by Bristol-Myers Squibb for the treatment of type 2 diabetes.
DPP-IV is the primary enzyme responsible for degradation
of incretins, such as glucagon-like peptide-1 (GLP-1), which is a
hormone responsible for the glucose-dependent stimulation of
insulin in humans. Inhibitors of DPP-IV serve as effective glucose
regulators by increasing the endogenous concentration of GLP-1.
-
Drug interactions
Potentially hazardous interactions with other drugs
None known